Extended Data Fig. 2: (related to Sub-heading, Safety of CAN-3110 in patients with rHGG/rGBM) Genomic alterations in 34/41 subjects (42 separate interventions) in the CAN-3110 clinical trial.
From: Clinical trial links oncolytic immunoactivation to survival in glioblastoma
34 rHGG/rGBM specimens underwent exome sequencing for the 18 genes shown on the left of the panel (PTEN, EGFR, etc). On the right side of the panel, the percentage of tumours expressing each genetic mutation is listed together with colour coded relative frequencies of specific types of genomic alteration (amplification, gain, etc). The top of the map displays a bar graph representation of tumour mutational burden (limited to these 18 genes), as well as indications of age, trial cohort, diagnosis at time of injection, and MGMT promoter methylation status for each patient included. To the far right of the figure, colour coding legends indicate designations for different types of genomic alteration, trial cohort, diagnosis, and MGMT promoter methylation status.
